Zota Health Care LImited has informed the Exchange about Investor Presentation
November 06, 2025
To, The Manager Listing Department, The National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400051
Dear Sir/Madam,
Trading Symbol: ZOTA
Sub: Investor Presentation
Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
With reference to the captioned subject we, Zota Health Care Limited are submitting herewith enclosed the Investor Presentation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The above information will also be available on the website of the Company at www.zotahealthcare.com.
This is for your information and record.
Thanking you,
Yours faithfully,
For Zota Health Care Limited
Ashvin Variya (Company Secretary & Compliance Officer) Place: Surat
Encl: a/a
Registered Office: Zota House, 2/896, Hira Modi Street, Sagrampura, Surat-395002 Ph: +91 261 2331601 Email: info@zotahealthcare.com Web: www.zotahealthcare.com
CIN: L24231GJ2000PLC038352
Investor Presentation
Zota Health Care Limited
Safe Harbour
This presentation has been prepared by the Zota Health Care Limited (the “Company”) only for information purpose to the stakeholders and does not contain any offer or invitation to subscribe to the securities of the Company. No offering of securities shall be made except by means of offer documents.
This presentation has been prepared on the basis of information and data available with the Company consider reliable. This presentation may not contain all the information that you may consider material. Any liability in respect of the content of or any omission from this presentation is expressly excluded.
Stakeholders are advised to compare the data provided in the presentation with the full financial results available on the website of the Company as well as on the website of the NSE. including “future oriented This presentation contains “forward-looking statements”, financial information” and “financial outlook”. These forward-looking statements are based on management’s current expectations and beliefs and are subject to uncertainty. Actual results may vary from the information contained in this presentation due to changes in government policies, regulations, economics reforms, natural calamities, competition, technology, etc. The company is not under any obligation to provide any update or alter forward looking statements, whether as a result of any new information or future events.
2
Company Overview
3
Zota Health Care Limited At a Glance
Zota Health Care Limited a publicly listed company on NSE, has established a significant footprint in the Indian healthcare sector since its inception in 2000.
Business Verticals
Headquartered in Surat, Gujarat.
Davaindia, launched in October 2017, is a retail generic pharmacy chain that provides quality generic medicines consisting of 2,000+ SKUs.
Davaindia
2,000+
SKUs in Davaindia portfolio
2,055+
Operational Davaindia Stores*
1,207 848
COCO Stores*
FOFO Stores*
Domestic Marketing Business
4,000+
Products covering major therapeutic segments
1,050+
Distributors currently, present across India
WHO-GMP
Recognized manufacturing partners
Exports
30+
Exports markets served
250+
Formulations manufactured for exports
325
Product approvals received out of 586 dossiers applications
Everyday Herbal Group
65.98% stake in Everyday Herbal Beauty Care Private Limited and 56% stake in Everyday Herbal Beauty and Wellness Care Private Limited strengthens Zota Health Care Limited’s supply chain and product development capabilities
Expands the product portfolio in over-the-counter (OTC) category
Financial Highlights (FY25 - Consolidated)
Total Revenue
₹ 29,297.28 lakhs
Gross Merchandise Value
₹ 24,562 lakhs
*As of September 30, 2025
4 4
Our Journey
Foundational Steps In Domestic Marketing
Setting Up Formulations Export Business
Strengthening Core And Pioneering Davaindia
2000
2004
2010
2011
2017
2018
Zota Health Care - Incorporated
Acquired all brand names of Sayona Medicare via an MOU
Inaugurated an export- oriented formulations manufacturing unit in Sachin, SEZ
Commenced exports, expanding business to African countries
2007
2012
2013
Acquired Mexon Health Care Limited's trademark and brand, including Health Park Laboratories and Aaron Biotech divisions
2010
Zota Pharmaceuticals and Atoz Pharmaceuticals merged with Zota Health Care
Secured WHO- GMP approval for the manufacturing unit at SEZ
2014
Obtained regulatory approvals from Kenya (PPB) and Sri Lanka (CDDA) for the Sachin SEZ plant
Acquired trademark and brand names of Redix Lifecare
2017
Received regulatory approval for SEZ plant from Tanzania (TFDA)
Listed on NSE - SME
Introduced Davaindia, a private sector generic pharmacy
2019
Opened ~150 Davaindia outlets
Migrated to the Main Board of NSE
2021
Achieved ₹10+ Cr in Export Sales; & 75+ Davaindia stores
2020
With over 250 outlets, Davaindia became the largest and fastest growing private sector generic pharmacy chain
2022
Davaindia secured its position as India’s largest private sector generic pharmacy with over 500 locations nationwide
Inception of COCO stores
2024
2023
Total Davaindia stores reaching 600
Everyday Herbal Group – 56% stake acquired, licensed by Khadi and Village Industrial Commission, Government of India.
2025*
Davaindia Expanded to 2055 no. of active stores with COCO 1207 & FOFO 848
*As of September 30, 2025
5
Management Profile
K e t a nk u ma r C h a n d ul al Z o t a C h a i r m a n a n d N o n - E x e c u t i v e D i r e c t o r
M o xesh K e t a nb hai Z o t a M a n a g i n g D i r e c t o r
D r. S uj i t P a u l G r o u p C h i e f E x e c u t i v e O f f i c e r
H i m a n s hu M u k t i l a l Z o t a W h o l e - t i m e D i r e c t o r
K a m l e s h R a j a ni k a nt Z o t a W h o l e - t i m e D i r e c t o r
Vi r e n M a n uk a nt Z o t a W h o l e - t i m e D i r e c t o r
6
Company’s Business Structure
Procurement in listed entity
Zota Health Care Limited (Listed entity)
Domestic Marketing Business
Export Operations
FOFO
(Sales to FOFO# stores)
FOFO Sales through Zota Health Care Limited
Step down subsidiary
Supplying products at ALP*
Davaindia
(Davaindia Health Mart Limited)
COCO
(COCO# stores)
COCO Sales through Davaindia Health Mart Limited
*ALP – Arm's length price
Business Verticals
# COCO – Company-Owned Company-Operated
FOFO – Franchisee-Owned Franchisee-Operated
7
Business Overview & Industry Dynamics
8
Revenue contribution (H1FY26)
Everyday Herbal Group
Exports
Domestic Marketing Business
73%
5%
8%
14%
15%
Davaindia
6%
74%
6%
Business Verticals
DAVAINDIA
• A Retail generic pharmacy chain providing quality generic medicines. • Focuses only on private-label products in:Nutraceutical Formulations • Medicinal | OTC | Ayurvedic | Cosmetic and Nutraceutical Formulations • Key emphasis is on chronic therapies and ailments. • COCO Stores are large format stores operated through our wholly-
owned subsidiary, Davaindia Health Mart Limited.
• FOFO Stores are operated on an asset-light franchise operated model.
Store variants
02 Company-Owned and Company- Operated (COCO) Franchisee-Owned and Franchisee- Operated (FOFO)
30% – 90% Savings on medicines as compared to equivalent branded generics
Large Store Network* 1,207 COCO stores 848 FOFO stores
100% private labelled products
DOMESTIC MARKETING BUSINESS
• Procures finished dosage forms from domestic formulations
manufactures and market them under own portfolio of brands
• Markets the products across the country through the distributors, who in turn, cater to retail pharmacies in their respective districts
1,050+ 4,000+
Distributors currently present across India
Products covering major therapeutic segments
WHO-GMP
Partners with WHO-GMP recognized manufacturers
EXPORT Operations
• Commenced manufacturing operations in 2010 at Sachin (SEZ) unit • The unit facilitates production of about 250 diverse formulations .
325
Product approvals out of 586 dossiers applications
30+ Countries
Zota Health Care Limited is majorly driven by its retail generic pharmacy chain Davaindia
EVERYDAY HERBAL GROUP
• Zota Health Care Limited’s 65.98% stake in the Everyday Herbal Beauty Care Private Limited & 56% in Everyday Herbal Beauty and Wellness Care Private Limited demonstrates a strategic move toward backward integration. This integration strengthens the product portfolio, particularly in the over-the-counter (OTC) segment, a key contributor to revenue
*As of September 30, 2025
9
Pharmacy Retail is a High Growth Opportunity within the Indian Retail Market
Indian Pharmacy Retail constitutes a large and expanding market opportunity
Operational Efficiency and Better Unit Economics drive Organized Pharmacy retail ahead of its Peers
(INR Billion)
1,725 173
1,552
FY20
4,793
1,198
16.1%
9.5%
3,595
26.9%
2,850
569
8.0%
2,281
FY25
FY30P
Modern Retail
Traditional
Pharmacy Retail Outpaces Broader Retail Growth in India
27%
Retail market (Organized) CAGR
20%
17%
16%
19%
15%
16%
14%
15%
11%
Pharmacy Retailing
Food & Grocery Retailing
Jewellery Retailing
Apparel Retailing
Food Services (QSR)
FY20-FY25
FY25-FY30E
Source: The Knowledge Company Research Notes: FY refers to financial year (1) % of store revenue (2) As of FY25
Retail Segment
Average Revenue per sq.ft. per year (INR)
Inventory costs (INR lakhs)
Inventory turnover
Promotional expense(1)
Employee Costs(1)
Capex (INR lakhs)
Store Level Payback Period
Steady State Store-Level ROCE Penetration of Organized Retail(2)
Omni-channel readiness
Share of Private Labels
Pharmacy
Food & Grocery
Jewellery
Apparel
Food Services (QSR)
30,000-50,000
~24,000
~1,40,000
~20,000
~26,000
10-20
28-30
3,000-4,000
~70
10-15
9-15x
12-15x
2x
3-4x
24x
~1%
3-5%
1-2%
5-8%
1-3%
1-2%
5-7%
4-5%
8-10%
9-12%
4-8
32-35
300-400
30-35
150-250
~3 yrs
~3 yrs
~3-4 yrs
~2-4 yrs
~3-4 yrs
45-50%
30-35%
20-25%
25-40%
25-35%
20%
High
9.5%
High
40%
Low
45%
50%
Medium
Medium
5-10%
15-20%
100%
Varies
100%
10
Zota Health Care Limited is strategically positioned to capitalize on the growth opportunities in Organized Pharmacy Retail
Organized Pharmacy Retail (by value) continues to Gain Momentum
Growth Drivers for Organized Pharmacy Retail
Pharmacy Retail (Organised)
Pharmacy Retail (Unorganised)
+10%
10%
90%
20%
80%
+5%
25%
75%
FY20
FY25
FY30E
1
3
5
7
Rising Urbanization
Improved digital infrastructure
Consumers’ preference for an enhanced retail experience
Assurance of authentic drugs
2
4
6
8
Increasing health awareness
Convenience offered by omni-channel services
Wider product assortment
Transparent discounting
Zota Health Care Limited (Davaindia) is positioned to take advantage of very low organized penetration across segments
Pharmacy Retail (Organized) penetration for FY25
28%
Metro & Mini Metros
22%
Tier I
10%
Tier II & beyond
44.68%
Growth in Revenue(1)
63.20%
Growth in Stores(2)
Source: The Knowledge Company Research Notes: FY refers to financial year (1) Growth of revenue from operations of Zota Health Care Limited (Davaindia) for FY23-FY25 (2) Growth in stores of Davaindia from FY23-FY25
11
Zota Health Care Limited | One of the Leading players in Pharmacy Retail Market in India
Share of Key Players in Modern B&M Pharmacy Outlets (FY25)
Zota Health Care Limited is the third largest Private Pharmacy Retailer in India (by number of stores) as of FY25
Apollo Pharmacies
Medplus
Davaindia
Wellness Forever
Emami Frank Ross
Thulasi Pharmacies
Others
0.5%
2.0%
2.4%
15.3%
9.9%
16,000
41.4%
28.5%
PMJAK
+ 16,912
No. of Stores (FY25)(1)
Apollo Pharmacies
6,626
Medplus
4,712
Davaindia
1,582
Wellness Forever
407
Zeno Health
260
Thulasi Pharmacies
85
Geographical Presence (States/UTs)
25/5
21/3
No. of Cities (FY25)
300+
1,200+
9/2
700+
4/0
50
FY 25(3)
Revenue - FY25 (Mn)(3)
2,929.75
1,15,444.00
61,360.53
14,943.17
Gross Margin (%)(3)
EBITDA Margin (%)(3)
Working Capital Turnover Ratio(3)
Inventory Turnover Ratio(3)
53.13%
-1.96%
4.82
1.72
20.37%
1.45%
-8.34
7.82
24.37%
7.94%
5.32
3.46
28.03%
5.28%
14.73
4.59
28/8
~800(2)
9,365.78
25.95%
16.93%
1.81
2.22
NA
NA(1)
3,146.60
16.61%
-22.03%
2.01
6.08
9
2/0
11
1,936.13
24.55%
1.41%
-6.81
7.31
3/0
34
1,882.39
16.27%
1.93%
33.75
6.50
Source: The Knowledge Company Research Notes: FY refers to financial year. (1) Truemeds has been left out as it is purely an e-commerce-based player. (2) Refers to number of districts. (3) FY24 data is provided for Wellness Forever, Pradhan Mantri Jan Aushadhi Kendra, Truemeds, Zeno Health and Thulasi Pharmacies. Numbers of Apollo Pharmacy, Truemeds, Thulasi, Zeno Health, Pradhan Mantri Jan Aushadhi Kendra are based on their FS (Standalone).
12
Zota Health Care Limited | Key Strengths
Exclusive focus on private label products in Davaindia
Wide product range with manufacturing tie-up
Pan-India customer reach and global presence
Efficient supply chain management
Strengths
Focused marketing activities to help achieve faster store maturity
Emphasis on COCO Model, which has helped growth
Focus on chronic therapies which promote high repeat business
Experienced Promoters and management team
13
DAVAINDIA
14
Davaindia - Retail Pharmacy Chain data
Revolutionizing the generic pharmacy industry with affordable, accessible, quality healthcare solutions through a chain of retail pharmacies
2000+
SKUs
2,055* Total no. of stores
1,207*
COCO stores
848*
FOFO Stores
•
•
•
Launched in October 2017, Davaindia has rapidly grown into India’s leading private-sector generic pharmacy chain expanded to 2,055 active stores as of September 30, 2025
Fundamentally driven by providing quality generic medicines at substantial discounts - remarkably 30% to 90% lower than their equivalent branded generics.
Focuses exclusively on private-label products in medicinal, OTC, ayurvedic, cosmetic and nutraceuticals categories, with a significant emphasis on chronic therapies and ailments
2 store Variants
• Company-Owned Company-Operated (COCO)
• Franchisee-Owned Franchisee-Operated (FOFO)
25* States
5* Union Territories
*As of September 30, 2025
15
Davaindia - Operating Model
Offers a cluster-based store model, optimizing accessibility and convenience for customers across diverse regions
2,000+ SKUs with 70% medicinal products and 30% OTC products, with a special emphasis on chronic ailments such as cardiac, diabetic and thyroid.
Cloud-based software and AI- based tools for real-time supply chain and operations management
CLUSTER BASED APPROACH
COMPREHENSIVE PORTFOLIO
TECHNOLOGY- BASED MODEL
Davaindia Health Mart Limited has implemented a hyperlocal e-commerce model for on-demand medicine delivery, leveraging its company-operated (COCO) retail outlets as fulfilment centres to ensure fast and efficient order processing and doorstep delivery.
HYPERLOCAL MODEL - Davaindia B2C Online Portal and Mobile App
COCO MODEL (NEW FORMAT STORES) Large-format, walk-in, Company-Owned Company- Operated stores in key metropolitans & cities across the country
EXCLUSIVE SALE
BRAND BUILDING
FOFO (Franchise) MODEL
100% of our product portfolio comprises exclusive sales of private-label generic medicines, OTC, and ayurvedic products
Brand building and consumer-facing advertisement and promotional campaigns
Franchisee-Owned Franchisee Operated stores adhere to an asset-light franchise operated model, contributing to scalability and accessibility
16
Davaindia - Eliminating traditional supply chain
By sourcing directly from manufacturers and selling straight to consumers, traditional pharma supply chain is eliminated & the cost benefits are transferred to the consumer
Doctors
Traditional Pharma
Davaindia Model
Manufacturer
Pharma Marketing Company
Distributors
Retailers
Consumers
Manufacturer
Consumers
Cost benefit to End Consumers
~30-90% savings on Davaindia medicines as compared to equivalent branded generics on expenses related to retailers, distributors and marketing.
17
Case Study – Savings on Davaindia’s margins
Company marketed by
Indian MNC 1
Indian MNC 2
Davaindia
Tablet
Molecule
Generic Type
MRP (INR)
Rosuvas 10 mg
Rosubest 10
Rosuvastatin 10
Rosuvastatin 10mg
Branded Generic
Trade Generic
Generic (Private Label)
345.5
119
23
Tablet
Telmisartan 40 mg & Hydrochlorothiazide 12.5 mg
Levocarnitine 500 mg
Rabeprazole 40 mg
Aceclofenac 100 mg, Paracetamol 325 mg & Serratiopeptidase 15 mg
Manufacturer
Same Manufacturer
Same Manufacturer
Same Manufacturer
Same Manufacturer
Marketed By
Foreign MNC
Indian MNC
Indian MNC
Indian MNC
MRP (INR)
193.7
23
437.8
76.5
208.6
32.5
148
32.5
Source: The Knowledge Company Research
18
Davaindia – What are COCO Stores
COCO stores are modern walk-in stores providing a distinct contrast to traditional counter-based pharmacies enhancing customer satisfaction and loyalty.
Expansion & growth
Number of COCO stores has grown from 101 stores in FY23 to 1,207 stores in H1FY26 (till September 30, 2025)
Efficient Inventory Management
With a working capital cycle of 30-40 days, COCO stores can maintain optimal inventory levels, thus reducing storage costs and potential wastage.
Company-Owned Company-Operated
(COCO)
19
Davaindia – COCO Stores
20
Davaindia - COCO Stores
1,207
Operational COCO stores
States
West Bengal
Uttar Pradesh
Company-Owned Company-Operated
No. of Stores
Operated by wholly-owned subsidiary Davaindia Health Mart Ltd
388
229
22
12
51
64
87
47
229
14
41
29
116
1
3
33
388
6
2
2
63
COCO
Company-Owned and Company-Operated
Maharashtra
Delhi
Enhancing Store Economics
Haryana
Kerala
Uttarakhand
Rajasthan
Telangana
Karnataka
Gujarat
Punjab
Madhya Pradesh
Himachal Pradesh
Chhattisgarh
Pondicherry
Odisha
Goa
Total
116
87
64
63
51
47
41
33
29
22
14
12
6
2
2
1
1,207
*As of September 30, 2025
21
Davaindia COCO - KPIs (1/2)
No. of Stores
Footfall
₹ in lakhs
1,207
852
55.10
52.60
253
101
20.70
7.75
FY23
FY24
FY25
H1FY26
FY23
FY24
FY25
H1FY26
H1FY26 As of September 30 ,2025
22
Davaindia COCO - KPIs (2/2)
GMV
₹ in lakhs
Average Wallet Spend
₹ in Lakhs
₹ 12,568
₹ 12,070
₹ 245
₹ 229
₹ 229
₹ 5,063
₹ 212
₹ 1,645
FY23
FY24
FY25
H1FY26
FY23
FY24
FY25
H1FY26
H1FY26 As of September 30 ,2025
23
Davaindia – What are FOFO Stores
Franchisee-Owned Franchisee-Operated (FOFO)
Asset-light franchise model
FOFO stores employ an asset-light franchise operated model.
Smaller Store size
FOFO stores are compact and over-the-counter format stores, typically having an average size of about 200-300 sq.ft.
24
Davaindia - FOFO Stores
3
9
15
848
Operational FOFO stores
13
6
2
12
42 1
30
28
167
26
9
164
1
112
57
1
43
2
9
65
4
2
9
16
17
As of September 30, 2025
FOFO
Franchisee-Owned and Franchisee-Operated
States Uttar Pradesh West Bengal Odisha Madhya Pradesh Gujarat Maharashtra Haryana Delhi Rajasthan Bihar Kerala Tripura Jammu & Kashmir Uttarakhand Karnataka Tamil Nadu Assam Jharkhand Punjab Telangana Arunachal Pradesh Himachal Pradesh Goa Andhra Pradesh Chhattisgarh Chandigarh Daman & Diu
Total
No. of Stores 167 164 112 65 57 43 42 30 28 26 16 15 13 12 9 9 9 9 6 4 3 2 2 2 1 1 1 848
25
Davaindia FOFO - KPIs (1/2)
No. of Stores
Footfall
₹ in lakhs
848
42.5
730
627
493
31.0
24.4
26.3
FY23
FY24
FY25
H1FY26
FY23
FY24
FY25
H1FY26
H1FY26 As of September 30 ,2025
26
Davaindia FOFO - KPIs (2/2)
GMV
₹ in lakhs
Average Wallet Spend
₹ in lakhs
₹ 11,994
₹ 282
₹ 282
₹ 281
₹ 8,703
₹ 6,739
₹ 7,411
₹ 276
FY23
FY24
FY25
H1FY26
FY23
FY24
FY25
H1FY26
H1FY26 As of September 30 ,2025
27
OTC (Over-the-counter) products
Strategic Acquisition as a move towards backward integration
Acquired 65.98% stake in the Everyday Herbal Beauty Care Private Limited & 56% in Everyday Herbal Beauty and Wellness Care Private Limited, licensed by the Khadi and Village Industrial Commission, a strategic move towards backward integration.
~30% SKUs
OTC products make up ~30% of the stock keeping units (SKUs) offered by our company making it an important part of the business
MOU with Everyday Herbal Group leverages the Rural Employment Guarantee Programme license granted by the Government of India, giving additional credibility and leveraging the well-known 'Khadi' mark.
H1FY26 OTC Revenue contribution
Khadi
27%
*Everyday Herbal Beauty Care Private Limited and Everyday Herbal Beauty and Wellness Care Private Limited
28 28
OTC – Products
29
Davaindia – Making Quality Healthcare, Affordable and More Accessible Across India
₹19,481 lakhs
Gross Merchandise Value (GMV) in H1FY26 COCO GMV – ₹12,070 lakhs FOFO GMV - ₹7,411 lakhs
2,055
Fast growing FOFO & COCO store network*
*As on September 30,2025
~60 %
Gross Margin in COCO format
30-90 %
Savings to consumers on Generic medicines
25-30 %
Mature COCO Stores EBITDA#
# Calculated prior to IND AS 116
30 30
State-Wise Presence of Davaindia Across India (COCO & FOFO Models)
States West Bengal Uttar Pradesh Maharashtra Delhi Odisha Haryana Gujarat Madhya Pradesh Kerala Rajasthan Uttarakhand Telangana Karnataka Punjab Bihar Tripura Himachal Pradesh Jammu & Kashmir Tamil Nadu Assam Jharkhand Chhattisgarh Arunachal Pradesh Goa Andhra Pradesh Pondicherry Chandigarh Daman & Diu
Total
* As on September 30, 2025
COCO 388 229 116 87 2 64 29 14 63 47 51 41 33 22 0 0 12 0 0 0 0 6 0 1 0 2 0 0 1,207
FOFO 164 167 43 30 112 42 57 65 16 28 12 4 9 6 26 15 2 13 9 9 9 1 3 2 2 0 1 1 848
Total 552 396 159 117 114 106 86 79 79 75 63 45 42 28 26 15 14 13 9 9 9 7 3 3 2 2 1 1 2,055
31
Davaindia’s Competitive Edge
The Main Focus of Davaindia: Affordable, Trustworthy, and Innovative Pharmacy Solutions
BENEFITS TO THE CUSTOMERS
BENEFITS TO THE PARTNERS
Medicines priced at low MRP thereby ensuring affordability for the masses
Private labels offered, helps in building customer trust by ensuring consistency
Continuously adding to its product range thereby offering variety
Products procured from WHO & GMP approved plants and quality attested
Store operations and the supply chain efficiently managed by cloud-based software & AI
Widespread marketing activities help in promoting the brand and improving sales
Elimination of distributors ensures timely supply of stock
32
Total Average (in %)
82%
Repeat Customers
Healthy Repeats
With a strong base of 82% repeat
customers, Davaindia demonstrates
a high level of customer satisfaction
and loyalty.
33 33
Higher Chronic category share Click to edit Master title style
CATEGORY MIX FY25
CATEGORY MIX H1FY26*
57%
60%
27%
16%
27%
13%
Chronic
OTC
Others
Chronic
OTC
Others
Higher chronic share: More than 50% of our revenue comes from chronic disease category, signalling high realization and retention rates, reflecting our crucial role in sustaining long-term patient care.
A strong emphasis is placed on chronic therapies and ailments such as cardiac, diabetic, thyroid, and neuropsychiatric, resonating with the core healthcare needs of our customers.
* As on September 30, 2025
34
Supply Chain Management Click to edit Master title style
• The Company has outsourced supply chain management to a third-party warehousing & logistics partner.
• A state-of-art central warehousing & processing center has been built in Surat.
35
Domestic Marketing Business
36
Marketing Value Chain:
Finished Dosage Form Manufacturers
WHO-GMP certified manufacturing partners
Distribution
Direct distribution to 1,050+ distributors spread across the country
Retail Pharmacies Ethical marketing, sales distribution and promotional activities undertaken by distributors
Domestic Marketing Business
This business vertical distributes generic drugs, OTC
products, and other pharmaceutical products through the
Company’s distribution network spread across India.
1,050+ Distributors spread across India
4,000+ Products in the portfolio
37
Export Operations
38
Export Operations
Dossiers Registered In Global Markets
1. Benin 2. Bolivia 3. Cambodia 4. Cameroon 5. Costa Rica 6. Ethiopia 7. Georgia 8. Ivory coast 9. Kenya 10. Mali 11. Myanmar 12. Nepal 13. Nigeria 14. South Africa
15. Sri Lanka 16. Swaziland 17. Tanzania 18. Turkmenistan 19. Uganda 20. Ukraine 21. Uzbekistan 22. Vietnam 23. Zambia 24. Kyrgyzstan 25. Libya 26. Yemen
Our Exports business vertical, which started in 2011, serves
clients in over 30 countries, mainly in the CIS, Latin America,
Africa, and Asia. At its plant in Sachin, SEZ, the Company
manufactures generic formulations for the dossiers it has
registered in overseas markets.
At present, the Company has registered over 325 dossiers,
while another 261 dossiers have been filed and are awaiting
approval from the relevant regulatory agencies.
250+*
Products manufactured
325*
Dossiers registered
261*
Dossiers pending approval
* As on September 30, 2025
39
Strategies
Zota Health Care Limited | Key Strategies
Expansion of Davaindia footprint with a focus on COCO model • Continued expansion using a cluster-based saturation strategy •
Increase presence in highly dense residential areas in larger cities
Continue marketing and brand building activities • Undertake multiple marketing and brand building activities • Store neighbourhood area focused marketing activities and door-to-door promotions
Increase supply chain localization and hyper local model pan-India with fast delivery • Expand warehouse capabilities to lower logistics costs and improve supply logistics • • Hyper local supply chain will be implemented through mobile application and website
Invest in improving operational efficiency throughout the organization
Expansion of product portfolio with a focus on OTC products • Grow our portfolio of products across therapeutic areas, focusing on chronic therapies •
Increase focus on OTC products
40
Financial Overview
41
Annually Financial Snapshot
Davaindia
₹ lakhs
Domestic Marketing Business ₹ lakhs
Export Operations
₹ lakhs
18,621.00
17,122.00
5,949.49
5,688.33
6,342.48
3,190.00
2,466.75
2,004.52
3,297.08
1,759.00
10,356.00
5,578.00
FY23
FY24
FY25
H1FY26
FY23
FY24
FY25
H1FY26
FY23
FY24
FY25
H1FY26
Davaindia has driven revenue growth, recording an impressive increase of ~ 82.71% CAGR since FY23 to FY25 .
42
₹ in lakhs
Particulars
Export Operations
Davaindia Sales
Domestic Marketing Business
Everyday Herbal Group Revenues from Operations
Cost of Goods Sold
Gross Profit
% Margin
Employee cost
Other expenses
Operational Exp
Operating Profit
% Margin
Other Income
EBITDA
% Margin
Depreciation
EBIT
Interest Cost
EBT
Taxes
Profit After Taxes
Profit & Loss Statement (Consolidated)
H1FY26
FY25
(Consolidated)
1,759.06
17,121.49
3,297.37
1,075.16 23,253.08
9,757.83
13,495.25
58.0%
7,137.03
5,330.50
12,467.53
1,027.72
4.4%
251.26
1,278.98
5.5%
3,318.63
-2,039.65
706.72
-2,746.37
250.77
-2,997.17
3,190.34
18,621.40
6,341.50
1,144.22 29,297.46
13,730.33 15,567.13
53.1%
8,606.62
7,533.82 16,140.44
-573.31
-1.96%
206.80 -366.51
-1.3%
4,319.61 -4,686.12
1,078.34 -5,764.46
-90.55 -5,673.89
43
Balance Sheet Statement (Consolidated)
As at 30th September 2025
As at 31st March 2025
Equity and Liabilities
As at 30th September 2025
As at 31st March 2025
(Consolidated)
₹ in lakhs
Assets
Non-Current Assets
Property, plant and equipment
Right-of-use assets
Intangible Assets
Capital Work in Progress
Intangible Assest Under Development
Financial Assets
(i) Investments
(ii) Loans
Deffered tax assets (Net)
Other Non Current Assets
Total Non Current Assets
Current Assets
Inventories
Trade Receivables
(i) Equity Share capital
5,598.94 (ii) Other Equity
12,538.11 Non-Controlling Interest
401.37 Total Equity 557.58 Liabilities
90.25 Non-Current Liabilities
Financial Liabilities
5,435.30 (i) Borrowings
11.02 (ii) Lease liabilities
865.22 Provisions
- Total Non Current Liabilities
25,497.79 Current liabilities
(i) Borrowings
10,568.38 (ii) Lease liabilities
7,593.49
16,211.75
417.84
651.48
858.02
9,228.37
11.02
1,176.50
-
36,148.47
11,783.36
5,814.18
Cash and Cash Equivalents
417.26
213.21
Bank Balance and other than Cash and Cash Equivalent Loans
Other Current Assets
Total Current Assets
Total Assets
214.51
4,060.50
2,152.52
24,442.33
60,590. 79
148.70 Other Current liabilities
1,699.06 Provisions
1,736.76 Total Current Liabilities
18,416.26 Total Liabilities
43,914.05 Total Equity and Liabilities
4,050.15
(ii) Trade payables Total outstanding dues of micro and small enterprises (ii) Trade payables Total outstanding dues of Creditors other than micro and small enterprises
3,064.38
28,510.11
311.51
31,886.00
503.92
13,187.45
602.53
14,293.90
163.91
4,287.88
1,715.46
2,863.50
19,504.98
347.00
22,715.48
499.48
10,255.49
382.21
11,137.18
60.95
3,144.45
1,248.17
4,533.80
2,991.91
806.17
2,903.68
14,410.90
28,704.80
60,590.79
1,008.34
1,607.55
10,061.37
21,198.55
43,914.05
44
Thank You
"ZOTA HOUSE", 2/896, Hira Modi Street, Sagrampura, Surat-395 002, Gujarat, India
cszota@zotahealthcare.com
www.zotahealthcare.com
45